| Submission | Nov. 29, 2024 |
| Submission [Line Items] | |
| Central Index Key | 0001806952 |
| Registrant Name | Lyell Immunopharma, Inc. |
| Form Type | S-3 |
| Submission Type | S-3 |
| Fee Exhibit Type | EX-FILING FEES |
| Offerings - Offering: 1 | Nov. 29, 2024 USD ($) shares |
| Offering: | |
| Fee Previously Paid | false |
| Other Rule | true |
| Security Type | Equity |
| Security Class Title | Common Stock, par value $0.0001 per share |
| Amount Registered | shares | 37,499,981 |
| Proposed Maximum Offering Price per Unit | 0.94 |
| Maximum Aggregate Offering Price | $ 35,249,982 |
| Fee Rate | 0.01531% |
| Amount of Registration Fee | $ 5,396.77 |
| Offering Note | (1) Estimated in accordance with Rule 457(c) solely for purposes of calculating the registration fee. The proposed maximum offering price per unit and the maximum aggregate offering price are based on the average of the $1.88 (high) and $0.98 (low) sales price of the registrant’s common stock as reported on the Nasdaq Global Select Market on November 22, 2024, which date is within five business days prior to the filing of this registration statement. (2) Shares of common stock registered for resale pursuant to this registration statement are shares which are to be offered by the selling securityholders named herein. In the event of a stock split, stock dividend or recapitalization involving the common stock, the number of shares registered shall automatically be adjusted to cover the additional shares of common stock issuable pursuant to Rule 416 under the Securities Act of 1933, as amended. |
| Fees Summary | Nov. 29, 2024 USD ($) |
| Fees Summary [Line Items] | |
| Total Offering | $ 35,249,982 |
| Previously Paid Amount | 0 |
| Total Fee Amount | 5,396.77 |
| Total Offset Amount | 0 |
| Net Fee | $ 5,396.77 |
